Michelle M. Ovanesian

May 23, 2024 | mondaq.com | Michelle M. Ovanesian |Joseph Drayton

The life sciences sector is in its "golden era" of innovation with the convergence of disciplines —including genetics, immunology, cell biology, and artificial intelligence—changing the speed, efficiency, and cost at which innovation occurs. With this era has come a fierce market for talent, resulting in the frequent movement of professionals between life sciences companies. Employee mobility in this space has not, however, gone unnoticed by the affected companies.

May 21, 2024 | jdsupra.com | Joseph Drayton |Michelle M. Ovanesian

The life sciences sector is in its “golden era” of innovation with the convergence of disciplines—including genetics, immunology, cell biology, and artificial intelligence—changing the speed, efficiency, and cost at which innovation occurs.  With this era has come a fierce market for talent, resulting in the frequent movement of professionals between life sciences companies. Employee mobility in this space has not, however, gone unnoticed by the affected companies.

Nov 30, 2023 | mondaq.com | Baldassare Vinti |Michelle M. Ovanesian |Daryl Leon

Life Sciences is an area ripe for trade secrets misappropriation litigation. In recent news, Merz Pharmaceuticals, LLC filed a lawsuit under the North Carolina Uniform Trade Secrets Act alleging that its former director of federal accounts, Andrew Thomas, stole trade secrets relating to Merz's flagship botulinum toxin drug Xeomin®.

Nov 29, 2023 | jdsupra.com | Daryl Leon |Michelle M. Ovanesian |Baldassare Vinti

Life Sciences is an area ripe for trade secrets misappropriation litigation. In recent news, Merz Pharmaceuticals, LLC filed a lawsuit under the North Carolina Uniform Trade Secrets Act alleging that its former director of federal accounts, Andrew Thomas, stole trade secrets relating to Merz’s flagship botulinum toxin drug Xeomin®.

Nov 28, 2023 | mindingyourbusinesslitigation.com | Nolan Goldberg |Michelle M. Ovanesian

In a recent public comment addressed to the United States Copyright Office, the Federal Trade Commission seemingly expanded upon remarks made at the National Advertising Division back in September that it will aggressively and proactively challenge alleged unfair practices involving artificial intelligence, even if that means stretching the meaning of “unfair” to increase its jurisdiction over such matters.